7
Participants
Start Date
July 31, 2012
Primary Completion Date
November 30, 2012
Study Completion Date
November 30, 2012
BMS-823778
Capsules, Oral, 2 mg, Once daily, 12 weeks
BMS-823778
Capsules, Oral, 6 mg, Once daily, 12 weeks
BMS-823778
Capsules, Oral, 15 mg, Once daily, 12 weeks
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 12 weeks
Local Institution, Budapest
Local Institution, Budapest
Local Institution, Budapest
Local Institution, Debrecen
Manassas Clinical Research Center, Manassas
National Clinical Research - Richmond, Inc., Richmond
National Clinical Research - Norfolk, Inc., Norfolk
Local Institution, Winston-Salem
Pharmquest, Llc, Greensboro
Pmg Research Of Salisbury, Salisbury
Local Institution, Shelby
Local Institution, Shelby
Metrolina Internal Medicine, Charlotte
Local Institution, Greenville
Local Institution, Atlanta
Local Institution, Coral Gables
Sterling Research Grp, Ltd., Cincinnati
Local Institution, New Orleans
Nea Baptist Clinic, Jonesboro
Local Institution, Layton
Local Institution, Los Angeles
Desert Medical Group Inc., Palm Springs
Pennington Biomedical Research Center, Baton Rouge
Anderson And Collins Clinical Research, Inc., Edison
Premier Research, Trenton
Syracuse Preventive Cardiology, Syracuse
Local Institution, Barranquilla
Local Institution, Bucaramanga
Local Institution, Cartagena
Local Institution, Manizales
Local Institution, Medellín
Local Institution, Balatonfüred
Local Institution, Ponce
Local Institution, Ödeshög
Local Institution, Stockholm
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY